Well-funded with multiple upcoming clinical milestones
29 September 2025 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces its unaudited interim results for the six months to 30 June 2025.
Highlights & Updates
|
• |
Cash balance of £10.0 million as at 30 June 2025, including £4.865 million gross proceeds raised as part of an oversubscribed and upsized fundraise |
|
• |
Cash runway extended into 2027, supporting the delivery of multiple key clinical milestones |
|
• |
Specialist blood cancer trials organisation Accelerating Clinical Trials Limited appointed to conduct POLB 001 Phase 2a trial, and supply of an approved bispecific antibody drug secured for the trial at no cost to the Company |
|
• |
Trial due to take place at The Christie NHS Foundation Trust and other leading UK specialist cancer centres, with interim data expected summer 2026 |
|
• |
POLB 001 granted Orphan Drug Designation by FDA as an oral preventative therapy for T-cell engager bispecific antibody-induced Cytokine Release Syndrome (“CRS”), further validating POLB 001’s scientific rationale and enhancing its commercial appeal |
|
• |
Positive data from an in vivo animal study in H1 2025 supported the use of POLB 001 to prevent CRS induced by T-cell engaging bispecific antibody therapies |
|
• |
Progress made towards commencement of oral GLP-1 proof of concept trial at University of Ulster, led by Prof Carel le Roux with up to 20 obese subjects, with topline data expected H1 2026 |
|
• |
The Company’s pipeline programmes are in areas of significant interest to the pharmaceutical industry and as such, Poolbeg anticipates strong potential for partnering on positive data from the forthcoming clinical trials |
Jeremy Skillington, PhD, Chief Executive Officer of Poolbeg, commented: “We have made excellent progress this year and have entered a catalyst-rich period for Poolbeg. Preparations for the POLB 001 Phase 2a trial are well advanced, with the approved bispecific antibody secured at no cost to the Company. The data from this study will further strengthen our extensive preclinical and clinical package, supported by the recent FDA Orphan Drug Designation, which underscores the strong scientific rationale behind POLB 001 and enhances its commercial appeal with prospective partners.
“Looking ahead, we anticipate a series of potential value-creating milestones as data emerges from our POLB 001 and Oral GLP-1 trials in 2026. This, combined with a robust cash runway and a team with proven expertise in clinical trial execution and deal-making, means that we believe we are well positioned to deliver value for shareholders. We look forward to providing further updates to the market in due course.”
Enquiries
|
Poolbeg Pharma Plc Jeremy Skillington, CEO Ian O’Connell, CFO |
+44 (0) 207 183 1499 |
About Poolbeg Pharma plc
Poolbeg Pharma plc (AIM: POLB) is a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field. The Company’s lead asset, POLB 001, has the potential to expand administration of cancer immunotherapies from centralised specialist cancer centres into community hospitals by making the treatments safer through the prevention of the life-threatening side effect, Cytokine Release Syndrome (CRS). As such, POLB 001 could increase the number of patients that can receive these life-saving treatments, thereby increasing the market opportunity. Poolbeg is also advancing the development of a patient-friendly therapy for obesity with an oral encapsulated GLP-1, offering a differentiated approach within one of the world’s largest markets. With multiple near-term clinical value inflection points, and an experienced team with a proven track record, Poolbeg is focussed on partnering its high value programmes that are targeting large markets and addressing critical unmet medical needs.
Stay updated: Website | Sign up for RNS alerts | Presentation | X | LinkedIn
